Healthcare
Coherus Biosciences Inc(CHRS)
Live Price
Offline$1.48
+0.00% today
1Y Change
+110.82%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $210.00M
- Revenue Growth
- -84.2%
- EPS Growth
- -680.0%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Coherus Biosciences Inc (CHRS) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $1.48 and up 110.8% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -84.2%, EPS growth of -680.0%, a dividend yield of 0.0%. What stands out right now is revenue -84.2%, EPS -680.0%, free cash flow -577.7% with operating margin -429.5% and ROIC -153.1%. Valuation is more restrained than many high-expectation growth names at P/E 1.3 and price/sales 5.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CHRS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-84.2% vs +7.6% peer median
Operating Margin
Below sector median
-429.5% vs +19.4% peer median
P/E
Below sector median
1.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -84.2% and EPS is at -680.0%, with operating margin around -429.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -17.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -12.3% | -23.6% | -27.2% |
2026 Mar 9, 2026 | +4.3% | +1.0% | -14.0% | -13.5% |
2025 Nov 6, 2025 | -3.1% | -10.1% | -15.4% | -19.5% |
Benchmark Edge
CHRS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CHRS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CHRS Max Drawdown
-45.82%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CHRS and SPY.
Company Overview
Coherus Biosciences Inc
NASDAQ
Coherus Biosciences Inc. is a commercial-stage biopharmaceutical company focused on oncology therapeutics. It develops and commercializes innovative treatments, including the FDA-approved next-generation PD-1 inhibitor LOQTORZI (toripalimab-tpzi), approved for nasopharyngeal carcinoma and other cancers. The company also offers UDENYCA, a biosimilar referencing Neulasta for supportive care in oncology, and YUSIMRY, a Humira biosimilar. Its pipeline features mid-stage clinical candidates like CHS-114, a selective anti-CCR8 antibody targeting regulatory T cells in solid tumors such as head and neck, gastric, esophageal, and colorectal cancers, and casdozokitug, an IL-27 antagonist for liver, lung, and other advanced solid tumors. Coherus Biosciences Inc. emphasizes proprietary combinations and synergies with industry partners to advance immuno-oncology treatments. Founded in 2010 and headquartered in Redwood City, California, it operates in the biotechnology sector, generating revenue primarily from the United States through its diversified portfolio of approved products.
- Leadership
- Mr. Dennis M. Lanfear
- Employees
- 228
- Street Address
- 333 Twin Dolphin Drive, Suite 600
- Mailing
- Redwood City, CA, 94065
- Region
- Redwood City, CA, United States
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 1.3
- EV/EBITDA
- โ
- Price/Sales
- 5.0
- Price/Book
- 3.5
Growth
- Revenue
- -84.2%
- EPS
- -680.0%
- Free Cash Flow
- -577.7%
Profitability
- Gross Margin
- 67.2%
- Operating Margin
- -429.5%
- Net Margin
- 398.4%
- ROE
- 789.4%
- ROIC
- -153.1%
Balance Sheet
- Debt/Equity
- 0.66
- Current Ratio
- 1.46
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.